Xero (ASX:XRO) passes the 2 million subscriber mark
07 Nov 2019 - Cloud accounting software company Xero (ASX:XRO) has passed the 2 million subscriber milestone and reports 32% per cent operating revenue growth.
07 Nov 2019 - Cloud accounting software company Xero (ASX:XRO) has passed the 2 million subscriber milestone and reports 32% per cent operating revenue growth.
07 Nov 2019 - MedAdvisor (ASX:MDR), Australia’s leading digital medication management company, has signed a new 2-year agreement with pharmacy retail group, Sigma Healthcare (ASX:SIG).
07 Nov 2019 - Technology company MGM Wireless (ASX:MWR) is thrilled that their SPACETALK children’s all-in-one smartphone SPACETALK will be sold in The Good Guys stores.
07 Nov 2019 - NAB (ASX:NAB) report their full year profits fell 10.6 per cent to $5.1 billion
07 Nov 2019 - Despite weak leads from US markets, the ASX looks set to open higher. Wall Street shares dropped after it was reported that President Donald Trump and Chinese President Xi Jinping’s meeting to sign an interim trade deal could be delayed until December. James Hardie (ASX:JHX) raised its full year adjusted net operating profit guidance.
07 Nov 2019 - nib Group (ASX:NHF) reaffirmed its financial year 2020 underlying operating profit guidance of at least $200 million, with statutory operating profit of at least $180 million.
07 Nov 2019 - South32 (ASX:S32) have entered into a binding conditional agreement for the sale of their 91.84 per cent shareholding in South32 SA Coal Holdings Proprietary.
06 Nov 2019 - Following a steady decline over the afternoon the S&P/ASX200 closed 0.6 per cent lower. Macquarie downgraded Blackmores (ASX:BKL) as an Underperform and reduces its 12-month price target to $58. Corporate Travel Management (ASX:CTD) confirmed its expectation for a 10 to 16.5% increase in EBITDA YoY.
06 Nov 2019 - The Australian share market opened lower despite positive leads from Wall Street and is now tracking flat at noon. Pendal Group (ASX:PDL) has topped the ASX best performers list despite a 23.5% decrease in NPAT compared to the prior corresponding period and a broker downgrade from Morgan Stanley.
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.